%0 Journal Article
%T Design, synthesis, and evaluation of novel 3,4-isoxazolediamide derivatives for the combination treatment of azole-resistant candidiasis.
%A Liu L
%A Sun Y
%A Gao Z
%A Yin W
%A Jiang H
%A Wu T
%A Sun Y
%A Qin Q
%A Zhao D
%A Cheng M
%J Arch Pharm (Weinheim)
%V 355
%N 12
%D Dec 2022
%M 36029272
%F 4.613
%R 10.1002/ardp.202200266
%X Invasive fungal infections are emerging as serious infectious diseases worldwide. Due to the frequent emergence of resistance, the cure for invasive fungal infections is often unachievable. The molecular chaperone Hsp90 provides a promising target because it supports survival, virulence, and drug resistance in a variety of pathogens. Herein, we report on the structural optimization and structure-activity relationship studies of 3,4-isoxazolediamide analogs. As a new class of fungal Hsp90 inhibitor, compound B25 was found to have good synergistic effects with fluconazole and to avoid potential mammalian toxicity. It also showed remarkable metabolic stability in vitro. Collectively, B25 could be a promising lead compound for drug discovery targeting fungal Hsp90 and deserves further investigation.